Semaglutide vs Cagrilintide
Semaglutide vs Cagrilintide: different appetite pathways and why CagriSema (the combo) is being studied.
The verdict
Semaglutide works the GLP-1 satiety pathway; Cagrilintide works the amylin pathway. They quiet hunger through two different signals, which is the whole reason the combination (CagriSema) is in late-stage trials, the appetite suppression stacks instead of overlapping. Semaglutide is the established, FDA-approved single agent and the sensible default on its own. Cagrilintide is most interesting as the add-on for people who plateaued on GLP-1 alone, not as a standalone replacement.
Semaglutide is the first wave of modern weight-loss drugs, sold as Ozempic and Wegovy. Single-receptor version of Tirzepatide. Slightly less effective and slightly rougher side effects, but well-studied and widely available.
Cagrilintide is an amylin agonist, a different appetite-control pathway than the GLP-1 drugs. Often paired with Semaglutide as 'CagriSema' for weight loss that breaks past GLP-1 plateaus. Once-weekly injection.
Which one should you pick?
Pick Semaglutide if beginners to glp-class peptides or users with insurance coverage on wegovy / ozempic.
Pick Cagrilintide if users plateaued on semaglutide or tirzepatide or people wanting cleaner satiety without bigger glp-1 nausea.
Still torn between Semaglutide and Cagrilintide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.